NeuroRx, a Wilmington biopharmaceutical company, has been granted fast-track status by the U.S. Food and Drug Administration for an experimental treatment for suicidal behavior. The company will begin enrolling patients in its sequential oral therapy ...
© 2022 Delaware Business Times
Holiday flash sale! Subscribe to Delaware Business Times and save 50%.
Limited time offer. New subscribers only.